Dublin, July 24, 2017 -- The "Global Nerve Repair Biomaterials Market - Trends and Forecast to 2024" report has been added to Research and Markets' offering.
Global Nerve Repair Biomaterials Market is Expected to Reach USD 775.6 Million by 2024, at a CAGR of 11.3% During the Forecast Period of 2017 to 2024
The new market report contains data for historic years 2014 & 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
The global nerve repair biomaterials market is witnessing a rapid growth due to increasing geriatric population, increasing incidence of nerve injuries and neurological disorders, favourable reimbursement policies, and increased government funding. The demand for nerve repair biomaterials is increasing in the hospitals followed by ambulatory trauma centres due to increasing aging population and rising number of nerve injuries and nerve surgeries.
Key Topics Covered:
1 Introduction
1.1. Overview of the Nerve Repair Biomaterials Market
1.2. Market Segmentation & Coverage
1.2.1. Currency and Pricing
1.2.2. Limitation
1.2.3. Stakeholders
2 Research Methodology
2.1. Key Takeaways
2.2. Arriving at the Global Nerve Repair Biomaterials Market Size
2.2.1. Market Crackdown Approach
2.2.2. Company Revenue and Market Share Analysis
2.2.3. Data Triangulation
2.2.4. Key Data Points from Primary Sources
2.2.5. Key Data Points from Secondary Sources
2.2.6. Porter's Five Forces Matrix
2.4. Global Nerve Repair Biomaterials Market: Research Snapshot
2.5. Assumptions
3 Market Landscape Summary
4 Premium Insights
4.1. Overview
4.2. Global Nerve Repair Biomaterials Market: Key Primary Insights
4.3. Market Overview
4.3.1. Drivers
4.3.1.1. Increasing Incidences of Peripheral Nerve Injuries
4.3.1.2. Technological Development in Nerve Repair
4.3.1.3. Favorable Reimbursement Policies
4.3.1.4. Expanded Target Applications
4.3.2. Restraints
4.3.2.1. Lack of Patient Awareness
4.3.2.2. Lack of Professionals, Including Trained Surgeons
4.3.3. Opportunities
4.3.3.1. Novel Therapies Such as Stem Cell Therapy
4.3.3.2. Rising Acceptance of Emerging Markets
4.3.4. Threats
4.3.4.1. Donor Site Morbidity
4.3.4.2. Inadequate Nerve Regeneration by Conduits
4.4. Key Market Trends and Upcoming Technologies
5 Executive Summary
6 Nerve Repair Biomaterials Market, by Product Type
6.1. Overview
6.2. Nerve Repair
6.2.1. Nerve Conduits
6.2.2. Nerve Grafts
6.2.2.1. Allografts
6.2.2.2. Acellularized Allografts
6.3. Nerve Protection
6.3.1. Nerve Protector
6.3.2. Nerve Wrap
7 Nerve Repair Biomaterials Market, by Injury Type
7.1. Overview
7.2. Epineural Nerve Repair
7.3. Perineural Nerve Repair
7.4. Group Fascicular Nerve Repair
8 Nerve Repair Biomaterials Market, by End User
8.1. Overview
8.2. Hospitals
8.3. Ambulatory Trauma Centers
8.4. Clinics
9 Nerve Repair Biomaterials Market, by Geography
10 Nerve Repair Biomaterials Market: Competitive Landscape
11 Nerve Repair Biomaterials Market, Company Profiles
- Axogen, Inc.
- Checkpoint Surgical, Inc.
- Collagen Matrix, Inc.
- Integra Lifesciences Corporation
- Polyganics B.V.
- Stryker Corporation
- Synovis Micro Companies Alliance, Inc.
For more information about this report visit https://www.researchandmarkets.com/research/hzf5jb/global_nerve
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Genomics, Biomaterials


Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
First Western Ship Transits Strait of Hormuz Since Iran War Began
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Britain Courts Anthropic Amid US Defense Department Dispute
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Apple Turns 50: From Garage Startup to AI Crossroads
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 



